Vault-13

GENENTA SCIENCE S P A GNTA

SPONSORED ADS · ADR · CUSIP 36870W100

5 institutional holders +2 vs Q1 2023
458,747458.7k shares reported held*
$2.7mreported value*
2 new 0 added 0 reduced 0 sold out net bought ≈ $2.4m (+413.2k shares)

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $5.96.

Trends to Q2 2023

Institutional holders

Managers reporting a position, each quarter

0246Q3 22: 3Q4 22: 5Q1 23: 3Q2 23: 55Q3 22Q4 22Q1 23Q2 23
Numbers
QuarterHolders
Q3 20223
Q4 20225
Q1 20233
Q2 20235

Buyers vs sellers

Managers adding to or starting a position, vs cutting or selling out

Bought or addedCut or sold out
404Q4 22: 3 bought or addedQ4 22: 0 cut or sold outQ4 22Q1 23: 0 bought or addedQ1 23: 2 cut or sold outQ1 23Q2 23: 2 bought or addedQ2 23: 0 cut or sold outQ2 23
Numbers
QuarterBought or addedCut or sold out
Q4 202230
Q1 202302
Q2 202320

Biggest buyers

Bank Julius Baer & Co. Ltd, Zurich New +412,547+412.5k
UBS Group AG New +700+700

Biggest sellers

None

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
Nuzzo Marco 13D · may seek influence -11.5 pts · filed 2026-10-02
Stated purposeItem 4 is hereby amended and supplemented by adding the following thereto: On June 12, 2026, the Court of Milan granted interim relief suspending the effectiveness of the resolution adopted at the Issuer's extraordinary shareholders' meeting on October 29, 2025 concerning the amendment to the Issuer's corporate purpose. On July 9, 2026, a panel of the Court of Milan revoked that interim relief following a challenge filed by the Issuer. The proceedings on the merits remain pending. Between August 7, 2026 and August 19, 2026, Fin Posillipo S.p.A. ("Posillipo") acquired 110,000 ADSs in open-market transactions at a price of $1.30 per ADS. Posillipo made these purchases for its own account. The purchases were not planned, directed, or coordinated by, and were not made pursuant to any agreeme… Full filing
11.5% -11.5 pts 5.5m 2026-10-02
Pierluigi Paracchi 13G · exempt (held before listing) -2.8 pts · filed 2026-01-27 9.8% -2.8 pts 2.3m 2026-01-27

Insider purchases and sales in Q2 2023

Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.

None reported in Q2 2023.

Holders, Q2 2023

#ManagerLocationShares Value% of their portfolioChangeShares change
1 Bank Julius Baer & Co. Ltd, Zurich 0.01% of their portfolio ZURICH, V8 412,547412.5k $2.5m $2.5m 0.01% New
2 ALGEBRIS (UK) LTD 0.13% of their portfolio London, X0 45,00045.0k $267.1k $267.1k 0.13% Unchanged
3 UBS Group AG 0.00% of their portfolio ZURICH, V8 700700 $4.1k $4.1k 0.00% New
4 MORGAN STANLEY 0.00% of their portfolio NEW YORK, NY 500500 $2.9k $2.9k 0.00% Unchanged
5 CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio BIRMINGHAM, AL 00 $0 $0 0.00% Unchanged